According to Adaptimmune Therapeutics's latest financial reports the company's current revenue (TTM) is £0.10 B. In 2023 the company made a revenue of £47.31 M an increase over the revenue in the year 2022 that were of £22.44 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.